MiR-466 targets RUNX2 and, therefore, leads to a suppression of RUNX2-related gene expression, such as AKT, OPN, matrix metalloproteinase-11 (MMP11) in prostate cancer cells [119]. This evidence concerns the gene MMP11 and prostate carcinoma.